We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-11.64%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$782M
AUM Growth
-$228M
Cap. Flow
+$27.9M
Cap. Flow %
3.57%
Top 10 Hldgs %
64.89%
Holding
44
New
7
Increased
12
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$40.7M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$29.8M
3
ACOR
Acorda Therapeutics
ACOR
+$17.2M
4
ARDX icon
Ardelyx
ARDX
+$17M
5
TGTX icon
TG Therapeutics
TGTX
+$15M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$102M
2
RGLS
Regulus Therapeutics
RGLS
+$16.2M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$14.8M
4
BPMC
Blueprint Medicines
BPMC
+$14.3M
5
COLL icon
Collegium Pharmaceutical
COLL
+$6.75M

Sector Composition

Rank Sector Weight
1 Healthcare 91.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
1
Wave Life Sciences
WVE
$1.11B
$98.4M 12.58%
7,088,651
– –
ACHN
2
DELISTED
Achillion Pharmaceuticals
ACHN
$92.9M 11.87%
12,033,220
+810,327
+7% +$5.93M
SIOX
3
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$57.4M 7.34%
625,000
– –
ACRS icon
4
Aclaris Therapeutics
ACRS
$743M
$49.8M 6.36%
2,627,719
+63,166
+2% +$1.21M
NKTR icon
5
Nektar Therapeutics
NKTR
$2.41B
$43.7M 5.59%
+211,924
New +$40.7M
ASND icon
6
Ascendis Pharma A/S
ASND
$16.5B
$40.1M 5.12%
2,161,366
+489,919
+29% +$8.7M
TGTX icon
7
TG Therapeutics
TGTX
$8.19B
$38.6M 4.94%
4,531,714
+1,717,935
+61% +$15M
AVXS
8
DELISTED
AveXis, Inc. Common Stock
AVXS
$37.1M 4.74%
+1,361,582
New +$29.8M
CHRS icon
9
Coherus Oncology
CHRS
$227M
$27M 3.45%
1,272,048
– –
ZGNX
10
DELISTED
Zogenix, Inc.
ZGNX
$22.6M 2.9%
2,451,237
+198,000
+9% +$1.98M
ARNA
11
DELISTED
Arena Pharmaceuticals Inc
ARNA
$18.4M 2.36%
936,411
+64,963
+7% +$1.04M
ARDX icon
12
Ardelyx
ARDX
$1.25B
$17.9M 2.28%
2,300,481
+1,729,037
+303% +$17M
AIMT
13
DELISTED
Aimmune Therapeutics
AIMT
$17.5M 2.24%
1,292,940
+502,740
+64% +$7.84M
CPXX
14
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$15.6M 1.99%
+1,414,114
New +$4.64M
NGNE icon
15
Neurogene
NGNE
$670M
$14.9M 1.91%
84,599
+3,600
+4% +$700K
CDTX
16
DELISTED
Cidara Therapeutics
CDTX
$14.9M 1.91%
58,711
– –
SGMO
17
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$13.4M 1.71%
2,212,036
– –
ACOR
18
DELISTED
Acorda Therapeutics
ACOR
$13.2M 1.68%
+4,151
New +$17.2M
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$13M 1.66%
2,428,571
– –
TARA icon
20
Protara Therapeutics
TARA
$227M
$12.6M 1.61%
40,673
+3,750
+10% +$1.21M
SBBP
21
DELISTED
Strongbridge Biopharma plc.
SBBP
$12.3M 1.57%
2,690,702
– –
DMTX
22
DELISTED
Dimension Therapeutics, Inc
DMTX
$12.1M 1.55%
1,548,033
+460,103
+42% +$3.62M
ARCT icon
23
Arcturus Therapeutics
ARCT
$168M
$11.5M 1.47%
433,273
– –
VTAE
24
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$10.4M 1.33%
1,575,000
+1,253,839
+390% +$11.4M
COLL icon
25
Collegium Pharmaceutical
COLL
$1.17B
$8.83M 1.13%
486,557
-371,126
-43% -$6.75M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, RA Capital Management held 44 positions worth $782M, down 23% from $1.01B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

RA Capital Management deployed $27.9M of net new capital in Q1 2016, opening 7 new positions and adding to 12 existing holdings. Its largest new stake was Nektar Therapeutics: 211,924 shares worth $43.7M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 85% a quarter earlier.

On the sell side, the largest reduction was Regulus Therapeutics, an estimated $16.2M trimmed.

  • RA Capital Management's largest Q1 2016 buy was Nektar Therapeutics: 211,924 shares worth $43.7M.
  • RA Capital Management added most to Ardelyx in Q1 2016, an estimated $17M increase.
  • RA Capital Management's biggest Q1 2016 reduction was Regulus Therapeutics, cutting an estimated $16.2M.
  • RA Capital Management fully exited DYAX CORPORATION in Q1 2016, selling an estimated $102M.
  • RA Capital Management's ten largest holdings make up 65% of its $782M portfolio in Q1 2016.
  • RA Capital Management opened 7 new positions and closed 2 in Q1 2016.
  • RA Capital Management's portfolio value fell 23% quarter-over-quarter to $782M.

Based on RA Capital Management's 13F filing for Q1 2016, filed 16 May 2016.